Non-Invasive Markers for Hepatic Fibrosis
Author Information
Author(s): Ancha Baranova, Priyanka Lal, Aybike Birerdinc, Zobair M Younossi
Primary Institution: Inova Health System, Falls Church, VA, USA; George Mason University, Fairfax, VA, USA; Inova Fairfax Hospital, Falls Church, VA, USA
Hypothesis
The development of non-invasive biomarkers for staging liver fibrosis is essential for the management of chronic liver diseases.
Conclusion
Non-invasive diagnostic tests for liver fibrosis, such as FibroScan and serum-based biomarkers, are promising but require further validation.
Supporting Evidence
- Current non-invasive methods include serum biomarker assays and advanced imaging techniques.
- FibroScan elastometry and serum-based APRI and FibroTest have gained the strongest clinical foothold.
- Non-invasive tests are recommended as pre-screening tools before definitive liver biopsy.
Takeaway
Doctors are trying to find easier ways to check for liver damage without needing to do a painful biopsy. Some tests are showing promise.
Methodology
This review systematically overviews non-invasive techniques and biomarkers for assessing liver fibrosis.
Limitations
Many non-invasive tests cannot accurately differentiate between early stages of fibrosis and often require further validation.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website